Fulcrum Therapeutics, Inc. FULC
Set alert
3.71 USD -0.06 -1.59%
At close · Oct 30
3.71 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
3.68 Day range 3.76
3.14 52-week range 14.60
- YTD
- -67.20%
- 1 year
- -56.86%
- Open
- 3.74
- Prev close
- 3.77
- Mkt cap
- 283.38M
- Vol
- 933.22K
- Avg vol
- 1.57M
- EPS
- -1.21
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.68
- High
- 3.76
- Forward P/E
- -3.84
- Beta
- 2.23
- Short ratio
- 7.67
- Inst. own
- 89.70%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 31, 2024
- 50-d avg
- 3.58
- 200-d avg
- 6.57
- 1y target
- 5.29
2Y chart
Events in this range
- Nov 13, 2024Earnings: -0.35; estimate -0.4; surprise 12.5%
- Nov 14, 2024Rating: HC Wainwright & Co. · Neutral → Neutral
- Nov 14, 2024Rating: RBC Capital · Sector Perform → Sector Perform
Signals (78)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 29, 2026 | 3 days ago |
| MACD: Buy Signal | Oct 27, 2026 | 5 days ago |
| MACD: Sell Signal | Oct 26, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 25, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Jun 18, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| RSI: Oversold | Jun 2, 2026 | 5 months ago |
| MACD: Buy Signal | May 27, 2026 | 5 months ago |
| RSI: Oversold | May 19, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 29, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 26, 2026 | 7 months ago |
| RSI: Oversold | Mar 24, 2026 | 7 months ago |
| RSI: Oversold | Mar 18, 2026 | 7 months ago |
| SMA: Bearish | Feb 27, 2026 | 8 months ago |
| SMA: Bullish | Feb 25, 2026 | 8 months ago |
| SMA: Bearish | Feb 24, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 24, 2026 | 8 months ago |
| SMA: Bearish | Feb 20, 2026 | 8 months ago |
| SMA: Bullish | Feb 19, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 11, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 4, 2026 | 9 months ago |
| SMA: Bearish | Jan 23, 2026 | 9 months ago |
| SMA: Bullish | Jan 22, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 22, 2026 | 9 months ago |
| SMA: Bearish | Jan 6, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 19, 2025 | 10 months ago |
| RSI: Overbought | Dec 9, 2025 | 10 months ago |
| SMA: Bullish | Dec 8, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 8, 2025 | 10 months ago |
| SMA: Bearish | Dec 2, 2025 | 11 months ago |
| MACD: Sell Signal | Dec 2, 2025 | 11 months ago |
| RSI: Overbought | Nov 24, 2025 | 11 months ago |
| RSI: Overbought | Nov 19, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 17, 2025 | 11 months ago |
| SMA: Bullish | Nov 13, 2025 | 11 months ago |
| SMA: Bearish | Nov 5, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 13, 2025 | 1 year ago |
| RSI: Overbought | Oct 8, 2025 | 1 year ago |
| RSI: Overbought | Sep 25, 2025 | 1 year ago |
| SMA: Bullish | Sep 16, 2025 | 1 year ago |
| SMA: Bearish | Sep 10, 2025 | 1 year ago |
| SMA: Bullish | Sep 5, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 27, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 25, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 22, 2025 | 1 year ago |
| SMA: Bearish | Jul 30, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 18, 2025 | 1 year ago |
| RSI: Overbought | Jul 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 9, 2025 | 1 year ago |
| RSI: Overbought | Jun 5, 2025 | 1 year ago |
| MACD: Sell Signal | May 30, 2025 | 1 year ago |
| MACD: Buy Signal | May 29, 2025 | 1 year ago |
| RSI: Overbought | May 28, 2025 | 1 year ago |
| MACD: Sell Signal | May 27, 2025 | 1 year ago |
| RSI: Overbought | May 8, 2025 | 1 year ago |
| RSI: Overbought | May 1, 2025 | 1 year ago |
| SMA: Bullish | Apr 17, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 9, 2025 | 1 year ago |
| RSI: Oversold | Apr 4, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 3, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 19, 2025 | 1 year ago |
| RSI: Oversold | Mar 13, 2025 | 1 year ago |
| RSI: Oversold | Mar 10, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 26, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 19, 2025 | 1 year ago |
| SMA: Bearish | Jan 31, 2025 | 1 year ago |
| SMA: Bullish | Jan 21, 2025 | 1 year ago |
| SMA: Bearish | Jan 17, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 8, 2025 | 1 year ago |
| RSI: Overbought | Dec 11, 2024 | 1 year ago |
| RSI: Overbought | Nov 27, 2024 | 1 year ago |
Key statistics
- Market cap
- 252.43M
- Enterprise value
- -41.98M
- Trailing P/E
- 0.00
- Forward P/E
- -3.84
- PEG ratio
- 0.00
- Price / sales
- 3.09
- Price / book
- 1.23
- EPS (TTM)
- -0.29
- Beta
- 2.23
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -24.79%
- Revenue (TTM)
- 81.63M
- Revenue growth
- 8990.90%
- Free cash flow
- -6.72M
- Total cash
- 273.78M
- Total debt
- 9.65M
- Return on equity
- -7.37%
- Shares outstanding
- 53.94M
- Short % of float
- 9.92%
- 50-day average
- 3.58
- 200-day average
- 6.57
Analyst view
Consensus: none
Price target (mean) 5.29 +42.5% upside
Now 3.71
- Target (low)
- 2.00
- Target (mean)
- 5.29
- Target (high)
- 14.00
Ratings (0m) 8 2 buy · 5 hold · 1 sell
- Strong buy1
- Buy1
- Hold5
- Sell0
- Strong sell1
Next earnings
Jul 31, 2024
Expected Jul 31, 2024. Consensus EPS estimate -0.28714.
Financials — quick view
FULC Revenue — quarterly 0
FULC Net income — quarterly -26.18M
FULC EPS — quarterly -0.34
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.40 | -0.35 | +0.05 | +12.50% |
| Jul 31, 2024 | Jun 1, 2024 | -0.06 | 0.87 | +0.93 | +1,550.00% |
| Jul 31, 2024 | Jun 1, 2024 | -0.06 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.44 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.44 | -0.43 | +0.01 | +2.27% |
| Feb 27, 2024 | Dec 1, 2023 | -0.44 | -0.40 | +0.04 | +9.09% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | RBC Capital | reit | Sector Perform | Sector Perform |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Sep 13, 2024 | RBC Capital | down | Outperform | Sector Perform |
| Sep 13, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Sep 12, 2024 | Leerink Partners | down | Outperform | Market Perform |
| Sep 12, 2024 | B of A Securities | down | Neutral | Underperform |
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. It has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fulcrumtx.com
News
- Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Has Average Target Price of $8.20
- Are BWIN, PTC, FULC, PRTH Obtaining Fair Deals for their Shareholders?
- Are BWIN, PTC, FULC, PRTH Obtaining Fair Deals for their Shareholders?
- Kaplan Fox is Investigating Claims Against Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors
- Kaplan Fox Encourages Fulcrum Therapeutics, Inc. (FULC) Investors Who Suffered Losses to Learn About Their Legal Rights
- Kaplan Fox Investor Alert: Fulcrum Therapeutics, Inc. (FULC) Investigated for Possible Securities Law Violations
- Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) and its Board for Possible Securities Law Violations
- Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of a Pending Securities Investigation
- Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of “Reduce” from Brokerages
- Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (FULC) Investors: The Firm is Investigating Possible Securities Law Violations
Your note
Sign in to keep a note on FULC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GOULD ROBERT J. | Chief Executive Officer | Sale | Jan 12, 2023 | 499,864 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 19, 2023 | 0 |
| SAPIR ALEX | Chief Executive Officer | Conversion of Exercise of derivative security | Jul 2, 2024 | 193,360 |
| TOURANGEAU GREG | Officer | Sale | May 6, 2024 | 11,571 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 18.96% | 10,229,099 | 47.87M | Sep 29, 2024 |
| Blackrock Inc. | 10.58% | 5,706,527 | 26.71M | Sep 29, 2024 |
| TCG Crossover Management, LLC | 9.73% | 5,250,000 | 24.57M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 8.86% | 4,777,912 | 22.36M | Sep 29, 2024 |
| Vanguard Group Inc | 6.07% | 3,274,592 | 15.33M | Sep 29, 2024 |
| TRV GP IV, LLC | 4.34% | 2,343,154 | 10.97M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.43% | 1,852,255 | 8.67M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 3.01% | 1,626,094 | 7.61M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.45% | 782,473 | 3.66M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.18% | 636,809 | 2.98M | Aug 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Pharmaceuticals ETF | 0.92% | 493,858 | 2.31M | Sep 29, 2024 |
| iShares Biotechnology ETF | 0.75% | 407,174 | 1.91M | Oct 30, 2024 |